Phase 2 clinical trials with K-877 (pemafibrate): A promising selective PPAR-α modulator for treatment of combined dyslipidemia

Germán Camejo

doi:10.1016/j.atherosclerosis.2017.04.013

Phase 2 clinical trials with K-877 (pemafibrate): A promising selective PPAR-α modulator for treatment of combined dyslipidemia

Atherosclerosis. 2017 Jun:261:163-164. doi: 10.1016/j.atherosclerosis.2017.04.013. Epub 2017 Apr 15.

Author

Germán Camejo¹

Affiliation

¹ Division of Clinical Chemistry, Dept. of Laboratory Medicine, Karolinska Institute at Huddinge University Hospital, SE141 40, Stockholm, Sweden. Electronic address: german.camejo@telia.com.

PMID: 28434555
DOI: 10.1016/j.atherosclerosis.2017.04.013

No abstract available

Keywords: Atherogenic lipoprotein parameters; Clinical trials; Combined dyslipidemia; K-877; Pemafibrate; Residual cardiovascular risk; Safety; Selective PPAR-α modulator.

Publication types

Editorial
Comment

MeSH terms

Dyslipidemias*
Humans
Hypolipidemic Agents
Lipids
PPAR alpha*

Substances

Hypolipidemic Agents
Lipids
PPAR alpha